Abstract
Interferon-induced transmembrane protein 1 (IFITM1), a 17-kDa membrane protein, is generally known as a modulator in many cellular functions. Recent studies showed overexpression of IFITM1 in cancers and relationship between IFITM1 overexpression and tumor progression. However, the role of IFITM1 in lung cancer remains unclear. Here, we presented the overexpression of IFITM1 in lung cancer tissues and cell lines A549 and H460 using quantitative Real-Time RT-PCR. In vitro assay indicated IFITM1 silencing inhibited lung cancer cell proliferation, migration, and invasion. Further, in vivo assay showed that IFITM1 silencing markedly suppressed cell growth and metastasis of lung cancer in tumor-bearing BALB/c nude mice. Mechanistically, we found that IFITM1 silencing significantly alleviated the protein levels of β-catenin, cyclin D1, and c-Mycin lung cancer cells and tumor samples. Taken together, our study revealed the role of IFITM1 as a tumor promoter during lung cancer development and the possible molecular mechanism.
Highlights
Lung cancer, a common type of cancers in the world, is divided into two categories: small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) [1]
Before exploration of the role of Interferon-induced transmembrane protein 1 (IFITM1) in lung cancer, we examined its expression in lung cancer tissues and corresponding normal lung tissues using RT-PCR and western blot analysis
We detected the expression of IFITM1 in two lung cancer cell lines (A549 and H460) and a bronchial epithelial cell line (BEAS-2B)
Summary
A common type of cancers in the world, is divided into two categories: small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) [1]. Interferon-induced transmembrane protein 1 (IFITM1), a 17-kDa membrane protein, is part of membrane complexes transducing homotypic adhesion signals in lymphocytes [8,9,10] It was originally identified as Leu, a cell-surface membrane protein encoded on the short arm of chromosome 11 [11,12,13,14]. There have been studies showing overexpression of IFITM1 in some types of cancers such as gastrointestinal, colorectal, and breast cancers [22, 23] These studies have demonstrated a positive correlation of IFITM1 overexpression with tumor progression. It is poorly understood what role IFITM1 plays in lung cancer.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
